Erlotinib Tablet, Film Coated
Product Images NDC 0093-7663

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Erlotinib (NDC 0093-7663). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

Chemical structure of Erlotinib hydrochloride, the active ingredient in the prescription drug Erlotinib. The diagram shows the molecular formula with rings, bonds, and side chains including a chlorine hydrochloride component.*

FDA Label Image

Image 10

Erlotinib 25 mg film-coated tablets in a white rectangular box with blue and yellow accents. The package includes 60 tablets. The label displays the product name, strength, route of administration (oral), and the labeler, Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image 2

A Kaplan-Meier survival curve chart showing progression-free survival probability over time in months for Erlotinib compared to chemotherapy. The chart includes two lines representing Erlotinib and chemotherapy groups, with the number of patients at risk listed below the x-axis for both treatments at multiple time points up to 45 months.*

FDA Label Image

Image 3

A Kaplan-Meier survival curve chart showing overall survival probability over time in months for patients treated with Erlotinib compared to placebo. The y-axis represents survival probability from 0 to 1, and the x-axis shows time up to 36 months. Below the graph, the number of patients at risk for both Erlotinib and placebo is displayed at various time points.*

FDA Label Image

Image 4

A survival probability Kaplan-Meier curve comparing overall survival (months) between Erlotinib and placebo patient groups. The graph plots survival probability on the y-axis from 0 to 1 and time in months on the x-axis up to 30 months, with Erlotinib showing a higher survival curve over time. A table below lists the number of patients at risk in each group at various time points.*

FDA Label Image

Image 5

A Kaplan-Meier survival curve comparing overall survival (months) on the horizontal axis with survival probability on the vertical axis. The plot shows two lines representing patient survival for Erlotinib versus Placebo groups, with a table below listing the number of patients at risk over time for each group.*

FDA Label Image

Image 6

Label for Erlotinib Tablets 25 mg by Teva Pharmaceuticals USA, Inc., showing the 30 tablet count. The label includes a barcode, NDC number 0093-7662-56, and standard prescription drug warnings and usage instructions. The label design features a beige and white color scheme with the Teva logo.*

FDA Label Image

Image 7

Label for Erlotinib Tablets 100 mg by Teva Pharmaceuticals USA, Inc. The label indicates a package of 30 film-coated tablets for oral use. It includes the NDC number 0093-7663-56 and space for lot and expiration information, along with dosage warnings and directions for safe use.*

FDA Label Image

Image 8

Erlotinib 150 mg film-coated tablet packaging label from Teva Pharmaceuticals USA, Inc. The label shows the product name and strength prominently, with a white background and dark text.*

FDA Label Image

Image 9

Label for Erlotinib Tablets 150 mg by Teva Pharmaceuticals USA, Inc. The label indicates a bottle containing 30 film-coated tablets for oral use. Key details include the NDC number 0093-7664-56, and designated prescription use (Rx only). The label shows batch and expiration date fields and includes manufacturer information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.